Altimmune to Participate at Two Upcoming Investor Conferences
Get Alerts ALT Hot Sheet
Join SI Premium – FREE
GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:
- Jefferies Global Healthcare Conference (New York, NY)Wednesday, June 5, 2024Fireside Chat at 2:00 p.m. Eastern Time
- Goldman Sachs Global Healthcare Conference (Miami Beach, FL)Wednesday, June 12, 2024Fireside Chat at 9:20 a.m. Eastern Time
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About AltimmuneAltimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter
Company Contact:Richard Eisenstadt Chief Financial Officer Phone: 240-654-1450 [email protected]
Investor Contact:Lee RothBurns McClellanPhone: 646-382-3403[email protected] Julia WeilmanBurns McClellanPhone: 646-732-4443[email protected]
Media Contact:Danielle CanteyInizio Evoke CommsPhone: 619-826-4657[email protected]
Source: Altimmune, Inc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Crypto News: Pepeto DeFi Exchange Nears Launch Following Audit Completion and Final Testing Phase
- Corgi Insurance Welcomes Robert E. Barlow Jr. as EVP of Partnerships to Drive Expansion in Community Association and Property & Casualty Insurance
- What the XRP ICO Can Teach Us About Finding the Next 100x Crypto To Buy Today
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Jefferies & Co, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share